Between more than 70 applicants, Michelson Diagnostics Ltd, the Orpington, UK-based developer and manufacturer of laser scanners for use in non-melanoma skin cancer diagnosis & treatment is chosen to participate in the Future Health Mission 2011 to the USA. The event is taking place in San Francisco along with the annual J.P. Morgan Healthcare Investing Conference in early January.
Regarding to the mission organizers, the Future Health Mission 2011 may provide the businessmen responsible for these 20 growing healthcare technology companies with the opportunity to connect with key people from the US's top technology businesses. Those companies which are the most successful in the UK will manage a conference to meet the media from all over the world as well as investors and potential partners.
The Technology Strategy Board, UK Trade and Investment, Polecat, Silicon Valley Bank and McKinsey in addition to other sponsors will support and deliver the mission. The mission aims to help the businessmen in the UK's healthcare technology sector to deliver their businesses to the global marketplace. Michelson Diagnostics is one of the UK's most innovative healthcare technology companies. It manufactured a unique optical scanner, called 'VivoSight' which is being operated by the best clinicians in the USA and Europe to the raising problem of diagnosing and treating non-melanoma skin cancer.
The scanner gives a live image of the tissues structure hidden beneath the skin surface which helps dermatologists to take more accurate and better decisions about skin lesions. This scanner is potentially decreasing the cost while increasing the effectiveness of diagnosis and treatment so that make the patient less invasive and unpleasant. Due to the annually increase of non-melanoma skin cancer cases in USA, Michelson's VivoSight scanner is now operating attempts at multiple sites in USA and Europe, and has already received CE and FDA clearance for clinical use.
